Member Info for Yorkshirepragma

…” and anticipates strong news flow in the coming months”.!

News 3/4 down

Try emailing the author…?

Chemo treatments with reduced side effects given profile.

Https://www.precedenceresearch.com/oncology-market

Https://www.pwc.com/gx/en/services/deals/trends/health-industries.html

Https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

Chinook purchase @3.2bn for ‘rare disease’ drugs.

What is therefore the value of a broad range tried portfolio drug upgrade , and the upside potential of the Affimer platform ?

Certainly x2/3/4 multiples perhaps?

Let’s see.

RAH, well considered…this is an ‘unusually opportune ‘ eg of ( hesitant to use this term) magnificent tech, affimers being a robust sector.

Once in a lifetime opportunity for BPharma..they’ll be lining up.

A an’ old bold AZer…’ .

GLA ..not needed it’s a cert.

Yes W ,please consider your position…

Tim, ….assessing the science to date ,..it’s near 90% there. Pharma majors will have had discussions with AS , it’s that sort of industry…at a point am sure bid(ders) will break out .

The ‘platform’ is worth $$$??

Gl

Https://www.novartis.com/about/therapeutic-areas/cancer

Highly encouraging to see . More to follow?

Just reviewing the science…for those science bods (or other), take a look at Fiona’s last presentation , and see slide on comparator tech.

This is the reason why this is worth several $bn ….

GLA

Ice. Cool, well said …

All ducks coming into line, and key point is this is the ‘exploitation ‘ of a novel biotechnology, and not simply a single drug development.

I had a kind responsive email from the broker chap who valued all recently,and w we agreed to differ on the risk factor GF ,as Dox is a proven drug , Av not dealing with a strictly novel drug dev.

…as an ‘old bold Pharmo…’, mines a Guinness ..

GLA

Https://www.dvcstem.com/post/multiple-sclerosis-cure#:~:text=Mesenchymal%20stem%20cell%20(MSC)%20therapy,immune%20system%20and%20reduce%20inflammation.

Tim, Yes, and success has been sketchy to say the least. A breakthrough tech would be $++++

Sobi squired for $1.7bn by CTI Biopharma

10/5/23 . With a ‘ developed/ approved ’ product ,under competition from other developments? See CTI for details.

…."………

Avacta…Broader range ? Higher pot.? 3-6m…

GLA

Https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

Oncology remaining most attractive option…

GLA

The global Gene Therapy Market in terms of revenue was estimated to be worth $7.3 billion in 2022 and is poised to reach $17.2 billion by 2027, growing at a CAGR of 18.6% from 2022 to 2027. The new research study consists of an industry trend analysis of the market.

Plus plus…wow

….astonishingly hipot technology….gla